Related references
Note: Only part of the references are listed.Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project
C. C. Tigue et al.
BONE MARROW TRANSPLANTATION (2007)
Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner
Angela C. Hirbe et al.
BLOOD (2007)
Lenalidomide: The emerging role of a novel targeted agent in malignancies
Sujith Kalmadi et al.
DRUGS OF TODAY (2007)
The evolving role of lenalidomide in the treatment of hematologic malignancies
Efstathios Kastritis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2006)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Share Paper
